Streptococcus Salivarius

Overview

Streptococcus salivarius is a Gram-positive, facultatively anaerobic bacterium and one of the earliest colonizers of the human oral cavity. It dominates the tongue dorsum and saliva, representing up to 10% of the cultivable oral flora. S. salivarius occupies a paradoxical position in the WikiBiome framework: specific strains (K12, M18) are among the most validated oral probiotics, producing bacteriocins that suppress pharyngeal pathogens, while its detection in the gut — particularly in neonates or in disease states — often signals oral-gut microbial translocation, a marker of barrier compromise.

Metal Dependencies

S. salivarius relies primarily on manganese for its superoxide dismutase and central metabolic enzymes, a common strategy among streptococci that reduces dependence on iron. This manganese preference gives S. salivarius intrinsic tolerance to iron-limited environments — but also allows it to thrive when iron is supplemented, as documented with iron phosphate binders in chronic kidney disease.

Key Enzymes and Functional Features

  • Salivaricin A and B — Lanthibiotic bacteriocins (BLIS: bacteriocin-like inhibitory substances) that inhibit Streptococcus pyogenes, Streptococcus pneumoniae, and Streptococcus mutans. The K12 strain produces salivaricin A2 and B; the M18 strain targets cariogenic bacteria.
  • Urease — Some strains express urease that hydrolyzes urea to ammonia, raising local pH. In the oral cavity this may protect against acid-mediated caries; in the gut this activity can contribute to ammonia production relevant to hepatic encephalopathy.
  • EPS production — Produces fructans (levan, inulin-type fructooligosaccharides) that serve as prebiotics for other commensals.

Ecological Role

In the oral cavity, S. salivarius is a pioneer colonizer that establishes competitive exclusion against pathogenic streptococci. Its bacteriocin production creates a protective zone on the tongue and pharyngeal surfaces that reduces Group A streptococcal pharyngitis and halitosis.

In the gut, S. salivarius detection carries different significance depending on context:

  • In healthy adults, it represents normal oral-gut transit at low abundance
  • In preterm neonates, enrichment of S. salivarius (along with Rothia mucilaginosa) was detected in the gut microbiome before NEC onset, suggesting oral-origin organisms as early warning biomarkers for necrotizing enterocolitis [1]
  • In fibromyalgia, S. salivarius was among 19 differentially abundant zOTUs in a multi-omics diagnostic signature [2]
  • In chronic kidney disease, sucroferric oxyhydroxide (iron phosphate binder) notably enriches S. salivarius, suggesting iron tolerance enables expansion under high-iron conditions

Conditions Associated

ConditionContext
Pharyngeal healthProbiotic strains K12/M18 reduce streptococcal pharyngitis recurrence
necrotizing enterocolitisPre-NEC gut enrichment as oral-gut translocation marker
fibromyalgiaDifferentially abundant in multi-omics diagnostic signature
Pancreatic cancer31-fold enrichment in fecal microbiota of PC patients vs. controls

Cross-References

References (5)

  1. Xiao-Chen Liu, Ting-Ting Du, Xiong Gao et al. (2022). Liu 2022 — Gut microbiota and SCFAs as early predictive biomarkers for neonatal NEC (pilot). Frontiers in Microbiology. doi:10.3389/fmicb.2022.969656
  2. Duran-Gonzalez et al. (2025). Duran-Gonzalez 2025 — Multi-Omics Diagnosis of Fibromyalgia. Frontiers in Microbiology. doi:10.3389/fmicb.2025.1641185
  3. Liu H, Liu H, Liu C et al. (2022). Liu et al. 2022 — Gut Microbiome and the Role of Metabolites in the Study of Graves' Disease. Frontiers in Molecular Biosciences. doi:10.3389/fmolb.2022.841223
  4. Laurence Genton, Vladimir Lazarevic, Ozren Stojanovic et al. (2021). Metataxonomic and Metabolic Impact of Fecal Microbiota Transplantation From Patients With Pancreatic Cancer Into Germ-Free Mice: A Pilot Study. Frontiers in Cellular and Infection Microbiology. doi:10.3389/fcimb.2021.752889
  5. C. Iannuccelli, M. Favretti, G. Dolcini et al. (2025). Iannuccelli 2025 — Fibromyalgia: One Year in Review 2025. Clinical and Experimental Rheumatology